On November 1, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023 (Press release, Ideaya Biosciences, NOV 1, 2023, View Source [SID1234636677]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jefferies London Healthcare Conference
Tuesday, November 14th, 2023 at 8:00 AM GMT | 3:00 AM ET
Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
IDEAYA Biosciences Investor R&D Day
Monday, December 4th, 2023 at 8:00 AM ET
The IDEAYA Investor R&D Day will include participation from GSK and a key opinion leader that will showcase scientific insights and clinical development opportunities across IDEAYA’s synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, and the GSK partnered programs. In addition, IDEAYA will highlight its next generation initiatives in MTAP-deletion, including a wholly-owned program where a development candidate nomination is targeted in 2024, further advancing IDEAYA’s multi-pronged strategy.
Pre-registration will be available through IDEAYA’s investor relations events page at View Source
A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source. A replay of available webcasts will be accessible for 30 days following the live event.